Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Operations: 2015-2025

Historic Cash from Operations for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to -$30.8 million.

  • Editas Medicine's Cash from Operations rose 41.35% to -$30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$179.6 million, marking a year-over-year increase of 1.18%. This contributed to the annual value of -$210.3 million for FY2024, which is 59.09% down from last year.
  • As of Q3 2025, Editas Medicine's Cash from Operations stood at -$30.8 million, which was up 38.57% from -$50.2 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Cash from Operations registered a high of -$22.2 million during Q4 2023, and its lowest value of -$57.1 million during Q2 2024.
  • Over the past 3 years, Editas Medicine's median Cash from Operations value was -$47.8 million (recorded in 2025), while the average stood at -$42.8 million.
  • Per our database at Business Quant, Editas Medicine's Cash from Operations spiked by 47.39% in 2023 and then slumped by 128.25% in 2024.
  • Quarterly analysis of 5 years shows Editas Medicine's Cash from Operations stood at -$34.6 million in 2021, then fell by 22.24% to -$42.3 million in 2022, then surged by 47.39% to -$22.2 million in 2023, then slumped by 128.25% to -$50.8 million in 2024, then soared by 41.35% to -$30.8 million in 2025.
  • Its Cash from Operations was -$30.8 million in Q3 2025, compared to -$50.2 million in Q2 2025 and -$47.8 million in Q1 2025.